NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.54 · Revenue $0.00 · 1 analysts
Est. EPS $-4.11 · Revenue $0.00 · 1 analysts
Est. EPS $-4.41 · Revenue $0.00 · 1 analysts
Est. EPS $-4.11 · Revenue $106.56M · 2 analysts
EPS $-0.16 · Revenue $0.00
EPS ¥-0.16 · Revenue ¥0.00
EPS ¥-0.07 · Revenue ¥0.00
EPS ¥-0.28 · Revenue ¥0.00
EPS ¥-4.46 · Revenue ¥0.00
EPS ¥-0.25 · Revenue ¥0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-6.6M | +95.9% | +35.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-20.6M | +94.6% | -211.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1.3% | -31.2% | +5.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 8.09x | -61.3% | -44.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $37.2M | -97.6% | -99.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.16 vs -0.77 | +79.2% | -0.09 vs -0.24 | +63.7% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Xu Cong Claire | officer: EVP, Clinical Development | Ordinary Shares | D | 3,282 | $0.79 |
| Aug 30, 2026 | Xu Cong Claire | officer: EVP, Clinical Development | Ordinary Shares | A | 9,382 | — |
| Aug 30, 2026 | Xu Cong Claire | officer: EVP, Clinical Development | Restricted Share Units | D | 4,079 | — |
| Aug 22, 2026 | Lenz Robert A. | director | Ordinary Shares | A | 17,218 | — |
| Aug 22, 2026 | Lenz Robert A. | director | Restricted Share Units | D | 7,486 | — |
| Name | Title | Gender | Year Born | Status |
|---|---|---|---|---|
Srishti Gupta | Chief Executive Officer & Director | — | 1976 | Active |
Cong Xu | Senior VP and Head of R&D Center of Excellence | — | 1985 | Active |
Phillip Dennis | Chief Medical Officer | — | 1963 | Active |
Xi-Yong Fu | Chief Executive Officer & Director | — | 1972 | Active |
Mark Hagler | President & Chief Commercial Officer | Male | — | Active |
Ming Lei | Chief Financial Officer | Male | 1997 | Active |
Sean Wuxiong Cao | Chief Business Development Officer & Director | Male | 1967 | Active |
Tyler Ehler | Senior Director of Investor Relations | Male | — | Active |
Wei Fu | Executive Chairman | Male | 1982 | Active |
Liwei Lin | General Counsel & Board Secretary | Female | 1988 | Active |
Woodside Energy Group (ASX: WDS) (NYSE: WDS):2026 full-year guidancePriorCurrentTotal production volumes3MMboe172-186174-185Gas hub exposure4%~30No changeCapita
ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at NovaBridge Biosciences Shanghai office, 38F, AIA Tower, No. 866 Dongchangzhi Road, Shanghai, China on September 8, 2026 at 10:00 a.m. (Shanghai time).
Shares of I-Mab (NASDAQ: NBP - Get Free Report) dropped 4.9% during mid-day trading on Wednesday. The company traded as low as $1.7150 and last traded at $1.74. Approximately 354,237 shares were traded during mid-day trading, a decline of 50% from the average session volume of 705,434 shares. The stock had previously closed at $1.83.
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026.
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA) whose tumors are both Claudin 18.2 (CLDN18.2) and PD-L1 positive.
